Novo Nordisk is defending its weight-loss drugs Rybelsus, Wegovy and Ozempic
Edugrafo / Shutterstock.com
25 February 2026NewsAmericasLiz Hockley

Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices

The Danish company is contending with fierce competition, a clinical trial setback and a UK boost to its main rival, while making new moves to enforce its weight-loss-drug IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
19 May 2026   In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".
Americas
19 May 2026   The award could rise to several billions under federal antitrust law, after the pharma company was found to have engaged in anticompetitive conduct over constipation drug Amitiza.
Americas
18 May 2026   A US court has refused to throw out AbbVie's claim that a former scientist brought its cancer drug secrets to a Chinese rival.